Leuko, an MIT startup developing PointCheck, the first solution that enables at-home noninvasive white blood cell (WBC) monitoring, announced a first closing of $5 million for their Series A round. The new funding, from HTH VC, Good Growth Capital, IAG Capital Partners, Nina Capital, and angel investors.

Leuko is a startup spun out from MIT and the Madrid M+Vision Consortium and founded by Carlos Castro-Gonzalez, Ian Butterworth, Aurelien Bourquard, and Alvaro Sanchez-Ferro. They are developing a platform technology, PointCheckTM, that combines optics and AI to make noninvasive blood testing easier, faster and more accessible than state-of-the art solutions. For its first application, Leuko aims to improve clinical outcomes for >2M cancer chemotherapy patients a year, reduce their chemotherapy-related hospital readmissions by 50% and save >$6B annually in healthcare cost.